European Union - English - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - umeclidinium bromide - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).,

European Union - English - EMA (European Medicines Agency)

glaxosmithkline trading services limited - umeclidinium bromide - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - rolufta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).,

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - umeclidinium bromide - inhalation powder - 65microgram/1dose

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - umeclidinium as bromide - powder for inhalation - umeclidinium as bromide 55 mcg - umeclidinium bromide - incruse is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).

Canada - English - Health Canada

glaxosmithkline inc - umeclidinium (umeclidinium bromide) - powder - 62.5mcg - umeclidinium (umeclidinium bromide) 62.5mcg - antimuscarinics antispasmodics

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxo operations uk ltd - umeclidinium (umeclidinium bromide) - powder for inhalation - 62.5mcg/dose

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - umeclidinium bromide 74.2 mcg (micronised) eqv. umeclidinium - powder, metered - umeclidinium bromide 74.2 mcg (micronised) eqv. umeclidinium 62.5 mcg/dose

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - umeclidinium bromide 74.2ug equivalent to umeclidinium 62.5 mcg;   - powder for inhalation - 62.5 mcg - active: umeclidinium bromide 74.2ug equivalent to umeclidinium 62.5 mcg   excipient: lactose monohydrate magnesium stearate - incruse ellipta is indicated as a long-term once daily maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).